- melanoma, kidney cancers, ovarian cancers
- novel therapies for the above
Professor Martin Gore has both a private and an NHS practice at The Royal Marsden. He is Professor of Cancer Medicine at The Institute of Cancer Research, and a Consultant Medical Oncologist in the gynaecological cancer, melanoma and kidney cancer units.
He qualified in medicine at St Bartholomew’s Hospital, London, and spent time in general practice before training in general internal medicine at University College Hospital, London.
He joined the Ludwig Institute of Cancer Research in 1981 where he worked as a clinical scientist and was awarded a PhD for his work on breast cancer. He joined the training programme at The Royal Marsden and was appointed Consultant Cancer Physician to The Royal Marsden and Senior Lecturer at The Institute of Cancer Research.
Professor Gore was a founder Senior Investigator of the National Institute for Health Research and a former Chairman of the Department of Health’s Gene Therapy Advisory Committee. He is a past President of the UK Melanoma Study Group and a past Chair of the National Cancer Research Institute’s Melanoma Clinical Studies Group.
He has served on the Health and Safety Executive’s Scientific Advisory Committee on Genetically Modified Organisms, the Council of the International Gynaecologic Cancer Society, the Programme Committee of the Annual Meeting of the American Society of Clinical Oncology and he was co-founder of the European International Kidney Cancer Symposium.
Currently, he is a Commissioner on the Commission on Human Medicines at the Medicines and Healthcare Products Regulatory Agency where he also chairs the Oncology and Haematology Expert Advisory group and he is a member of the Oncology Scientific Advisory Group at the European Medicines Agency. He is also a co-Patron of the Rarer Cancers Foundation.
In 2014 he became the first non-US recipient of the Eugene P. Schonfeld Award Lecturer from The Kidney Cancer Association, a US-based patient advocacy group, which ‘recognises highly respected healthcare professionals who have made significant contributions in the treatment of renal cell carcinoma’.
He is the editor of the Gynaecological Cancer Section of Current Opinion in Oncology and has served on the editorial board of several journals including the Journal of Clinical Oncology. He has published more than 550 articles and edited 10 textbooks.
Professor Gore’s main research interests are the development of novel therapeutics in ovarian cancer, melanoma and renal cell carcinoma, particularly in the area of immunotherapy, gene therapy and targeted agents.